IP Library › Granted Patent US 8,778,346
Granted Patent B2
US 8,778,346 · App. 13/287,208 · Granted Jul 15, 2014

Anti-IL-23 antibodies

Inventors: Rachel Rebecca Barrett (Bethel, CT); Keith Canada (Southbury, CT); Katrina Mary Catron (Middlebury, CT); Robert Copenhaver (Portland, OR); Lee Edward Frego (Hopewell Junction, NY); Ernest Lee Raymond (New Milford, CT); Sanjaya Singh (Sandy Hook, CT); Xiangyang Zhu (Ridgefield, CT)
Assignee: Boehringer Ingelheim International GmbH
C07K16/244C07K2317/24C07K2317/76A61K2039/505C07K2317/92C07K2317/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,778,346
App. No.
13/287,208
Granted
Jul 15, 2014
Kind
B2
Abstract

The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same.

Claims (58)

1. An isolated anti-interleukin (IL)-23p19 antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises:

a) a light chain variable region comprising the amino acid sequence of SEQ ID NO:19 (CDR1-L); the amino acid sequence of SEQ ID NO:20 (CDR2-L); and the amino acid sequence of SEQ ID NO:21 (CDR3-L); and

b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 63, 66, 67 or 68 (CDR1-H); the amino acid sequence of SEQ ID NO:64 (CDR2-H); and the amino acid sequence of SEQ ID NO:65 (CDR3-H).

2. An anti-IL-23p19 antibody according to claim 1 , wherein said antibody is a monoclonal antibody.

3. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claim 2 and a pharmaceutically acceptable carrier.

4. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claim 1 and a pharmaceutically acceptable carrier.

5. An isolated anti-IL-23p19 antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises:

a) a light chain variable region comprising the amino acid sequence of SEQ ID NO:19 (CDR1-L); the amino acid sequence of SEQ ID NO:20 (CDR2-L); and the amino acid sequence of SEQ ID NO:21 (CDR3-L); and

b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:63 (CDR1-H; the amino acid sequence of SEQ ID NO:64 (CDR2-H); and the amino acid sequence of SEQ ID NO:65 (CDR3-H).

6. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claim 5 and a pharmaceutically acceptable carrier.

7. An isolated anti-IL-23p19 antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises:

a) a light chain variable region comprising the amino acid sequence of SEQ ID NO:19 (CDR1-L); the amino acid sequence of SEQ ID NO:20 (CDR2-L); and the amino acid sequence of SEQ ID NO:21 (CDR3-L); and

b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:66 (CDR1-H; the amino acid sequence of SEQ ID NO:64 (CDR2-H); and the amino acid sequence of SEQ ID NO:65 (CDR3-H).

8. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claim 7 and a pharmaceutically acceptable carrier.

9. An isolated anti-IL-23p19 antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises:

a) a light chain variable region comprising the amino acid sequence of SEQ ID NO:19 (CDR1-L); the amino acid sequence of SEQ ID NO:20 (CDR2-L); and the amino acid sequence of SEQ ID NO:21 (CDR3-L); and

b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:67 (CDR1-H; the amino acid sequence of SEQ ID NO:64 (CDR2-H); and the amino acid sequence of SEQ ID NO:65 (CDR3-H).

10. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claim 9 and a pharmaceutically acceptable carrier.

11. An isolated anti-IL-23p19 antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises:

a) a light chain variable region comprising the amino acid sequence of SEQ ID NO:19 (CDR1-L); the amino acid sequence of SEQ ID NO:20 (CDR2-L); and the amino acid sequence of SEQ ID NO:21 (CDR3-L); and

b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:68 (CDR1-H; the amino acid sequence of SEQ ID NO:64 (CDR2-H); and the amino acid sequence of SEQ ID NO:65 (CDR3-H).

12. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claim 11 and a pharmaceutically acceptable carrier.

13. An isolated anti-IL-23p19 antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the amino acid sequence of any one of SEQ ID NO:158, 160, 162 or 164; and a heavy chain variable region comprising the amino acid sequence any one of SEQ ID NO:166, 168, 170 or 172.

14. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claim 13 and a pharmaceutically acceptable carrier.

15. An isolated anti-IL-23p19 antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:160 and a heavy chain variable region comprising the amino acid sequence SEQ ID NO:166.

16. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claim 15 and a pharmaceutically acceptable carrier.

17. An isolated anti-IL-23p19 antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:160 and a heavy chain variable region comprising the amino acid sequence SEQ ID NO:168.

18. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claim 17 and a pharmaceutically acceptable carrier.

19. An isolated anti-IL-23p19 antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:158 and a heavy chain variable region comprising the amino acid sequence SEQ ID NO:166.

20. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claim 19 and a pharmaceutically acceptable carrier.

21. An isolated anti-IL-23p19 antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:158 and a heavy chain variable region comprising the amino acid sequence SEQ ID NO:168.

22. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claim 21 and a pharmaceutically acceptable carrier.

23. The isolated anti-IL-23p19 antibody or antigen-binding fragment thereof according to claim 13 , wherein the antibody or antigen-binding fragment thereof comprises the amino acid sequence of SEQ ID NO:166 or 168 linked to a human IgG1 heavy chain constant region; and the amino acid sequence of SEQ ID NO:158 or 160 linked to a human kappa light chain constant region.

24. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claim 23 and a pharmaceutically acceptable carrier.

25. An anti-IL-23p19 antibody or antigen-binding fragment thereof comprising:

a) a humanized light chain variable domain comprising the CDRs of SEQ ID NO:158 or 160 and framework regions having an amino acid sequence at least 90% identical to the amino acid sequence of the framework regions of the variable domain light chain amino acid sequence of SEQ ID NO:158 or 160; and

b) a humanized heavy chain variable domain comprising the CDRs of SEQ ID NO:166 or 168 and framework regions having an amino acid sequence at least 90% identical to the amino acid sequence of the framework regions of the variable domain heavy chain amino acid sequence of SEQ ID NO:166 or 168.

26. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claim 25 and a pharmaceutically acceptable carrier.

27. A monoclonal anti-IL-23p19 antibody comprising a light chain variable region comprising the amino acid sequence selected from the group consisting of any one of SEQ ID NO:158, 160, 162 and 164 and a heavy chain variable region comprising the amino acid sequence selected from the group consisting of any one of SEQ ID NO:166, 168, 170 and 172.

28. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claim 27 and a pharmaceutically acceptable carrier.

29. A monoclonal anti-IL-23p19 antibody comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:160 and a heavy chain variable region comprising the amino acid sequence SEQ ID NO:166.

30. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claim 29 and a pharmaceutically acceptable carrier.

31. A monoclonal anti-IL-23p19 antibody comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:160 and a heavy chain variable region comprising the amino acid sequence SEQ ID NO:168.

32. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claim 31 and a pharmaceutically acceptable carrier.

33. A monoclonal anti-IL-23p19 antibody comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:158 and a heavy chain variable region comprising the amino acid sequence SEQ ID NO:166.

34. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claim 33 and a pharmaceutically acceptable carrier.

35. A monoclonal anti-IL-23p19 antibody comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:158 and a heavy chain variable region comprising the amino acid sequence SEQ ID NO:168.

36. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claim 35 and a pharmaceutically acceptable carrier.

37. A monoclonal anti-IL-23p19 antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:174 or 180 and a heavy chain comprising the amino acid sequence of SEQ ID NO:176 or 178.

38. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claim 37 and a pharmaceutically acceptable carrier.

39. A monoclonal anti-IL-23p19 antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:174 and a heavy chain comprising the amino acid sequence of SEQ ID NO:176.

40. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claim 39 and a pharmaceutically acceptable carrier.

41. A monoclonal anti-IL-23p19 antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:174 and a heavy chain comprising the amino acid sequence of SEQ ID NO:178.

42. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claim 41 and a pharmaceutically acceptable carrier.

43. A monoclonal anti-IL-23p19 antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO:180 and a heavy chain comprising the amino acid sequence of SEQ ID NO:176.

44. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claim 43 and a pharmaceutically acceptable carrier.

45. A monoclonal anti-IL-23p19 antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO: -180 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 178.

46. A pharmaceutical composition comprising an antibody or antigen-binding fragment according to claim 45 and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2013
From: BARRETT, RACHEL REBECCA; CANADA, KEITH; CATRON, KATRINA MARY; COPENHAVER, ROBERT; FREGO, LEE EDWARD; RAYMOND, ERNEST LEE; SINGH, SANJAYA; ZHU, XIANGYANG
To: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Reel/Frame 031296/0575 →
Continuity (5)
Provisional Application 61448785 · Mar 3, 2011
Provisional Application 61412594 · Nov 11, 2010
Provisional Application 61411953 · Nov 10, 2010
Provisional Application 61410158 · Nov 4, 2010
Related Publication 20120282269A1 · Nov 8, 2012